Get started
ERIS LIFESCIENCES LIMITEDERIS LIFESCIENCES LIMITEDERIS LIFESCIENCES LIMITED

ERIS LIFESCIENCES LIMITED

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

ERIS chart


Full chart

ERIS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪199.73 B‬ INR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
59.35
Basic EPS (TTM)
25.60 INR
Net income (FY)
‪3.92 B‬ INR
Revenue (FY)
‪20.09 B‬ INR
Shares float
‪33.65 M‬
Beta (1Y)
−0.06

Employees


Employees (FY)
‪3.08 K‬
Change (1Y)
−375 −10.85%
Revenue / Employee (1Y)
‪6.52 M‬ INR
Net income / Employee (1Y)
‪1.27 M‬ INR

About ERIS LIFESCIENCES LTD


Sector
Health Technology
CEO
Amit Indubhushan Bakshi
Headquarters
Ahmedabad
Website
eris.co.in
Founded
2007
ISIN
INE406M01024
FIGI
BBG00GX73BF8
Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. Its brands include Eritel, Glimsave, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The firm markets and distributes pharmaceutical drugs, such as tablets, syrups and injections. The company was founded by Amit Indubhushan Bakshi on January 25, 2007 and is headquartered in Ahmedabad, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ERIS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ERIS highest yielding bonds


873ELL26
ELL-8.73%-7-12-26-PVT
Yield to maturity
—
Maturity date
Dec 7, 2026
873ELL27
EEL-8.73%-7-6-27-PVT
Yield to maturity
—
Maturity date
Jun 7, 2027

Explore more bonds 

Frequently Asked Questions


The current price of ERIS is 1,467.45 INR — it has decreased by −3.27% in the past 24 hours. Watch ERIS LIFESCIENCES LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange ERIS LIFESCIENCES LIMITED stocks are traded under the ticker ERIS.
ERIS stock has risen by 1.27% compared to the previous week, the month change is a 5.57% rise, over the last year ERIS LIFESCIENCES LIMITED has showed a 67.51% increase.
We've gathered analysts' opinions on ERIS LIFESCIENCES LIMITED future price: according to them, ERIS price has a max estimate of 1,680.00 INR and a min estimate of 1,230.00 INR. Watch ERIS chart and read a more detailed ERIS LIFESCIENCES LIMITED stock forecast: see what analysts think of ERIS LIFESCIENCES LIMITED and suggest that you do with its stocks.
ERIS reached its all-time high on Dec 11, 2024 with the price of 1,593.00 INR, and its all-time low was 341.05 INR and was reached on Mar 30, 2020. View more price dynamics on ERIS chart.
See other stocks reaching their highest and lowest prices.
ERIS stock is 6.39% volatile and has beta coefficient of −0.06. Track ERIS LIFESCIENCES LIMITED stock price on the chart and check out the list of the most volatile stocks — is ERIS LIFESCIENCES LIMITED there?
Today ERIS LIFESCIENCES LIMITED has the market capitalization of ‪199.73 B‬, it has increased by 1.72% over the last week.
Yes, you can track ERIS LIFESCIENCES LIMITED financials in yearly and quarterly reports right on TradingView.
ERIS LIFESCIENCES LIMITED is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
ERIS LIFESCIENCES LIMITED revenue for the last quarter amounts to ‪7.41 B‬ INR, despite the estimated figure of ‪7.41 B‬ INR. In the next quarter, revenue is expected to reach ‪7.73 B‬ INR.
ERIS net income for the last quarter is ‪915.90 M‬ INR, while the quarter before that showed ‪831.80 M‬ INR of net income which accounts for 10.11% change. Track more ERIS LIFESCIENCES LIMITED financial stats to get the full picture.
ERIS LIFESCIENCES LIMITED dividend yield was 0.00% in 2023, and payout ratio reached 0.00%. The year before the numbers were 1.28% and 26.15% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 15, 2024, the company has ‪3.08 K‬ employees. See our rating of the largest employees — is ERIS LIFESCIENCES LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ERIS LIFESCIENCES LIMITED EBITDA is ‪8.38 B‬ INR, and current EBITDA margin is 34.88%. See more stats in ERIS LIFESCIENCES LIMITED financial statements.
Like other stocks, ERIS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ERIS LIFESCIENCES LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ERIS LIFESCIENCES LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ERIS LIFESCIENCES LIMITED stock shows the buy signal. See more of ERIS LIFESCIENCES LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.